Read more
List of contents
Part I. Introduction. Tumor-Associated Antigens and the Role of Antibodies and Cellular Immunity in Cancer. The Immunogenicity of Foreign Monoclonal Antibodies in Human Disease Applications: Problems and Current Approaches. Additive and Synergistic Interactions of Monoclonal Antibodies and Immunotoxins Reactive with Breast and Ovarian Cancer. Tumor Rejection Antigens of the Chemically Induced BALB/5 Meth A Sarcoma. Part II. Introduction. Antitumor Effector Cells: Characteristics and Basic Mechanisms. Phenotypic and Functional Characteristics of Human A-NK Cells. Regulation and Function of Fibronectin Receptors Expressed by Natural Killer Cells. Growth Requirements, Binding and Migration of Human Natural Killer Cells. Regulation of Monocytes by IL-2-Activated Killer Cells. Identification and Enrichment of Proteolytic Enzymes of IL-2 Activated Rat Natural Killer (A-NK) Cells: Potential Physiological Roles in NK Cell Function. Part III. Introduction. Animal Models in Tumor Biology. Effects of rhIL-7 on Leukocyte Subsets in Mice: Implications for Antitumor Activity. Up-Regulation of Tumor Cell Sensitivity to Natural Cell-Mediated Cytotoxicity by UV Light Irradiation. Studies on NK Cell Precursors in Mice. Part IV. Introduction. Tumor Microenvironment and Immune Effector Cells. Tumor-Infiltrating Lymphocytes in Human Solid Tumors. Localization of Immune Effector Cells to Tumor Metastases. Anti-tumor Effector Cells: Extravasation and Control of Metastasis I Tumor Microenvironment and Immune Effector Cells: Isolation, Large Scale Propagation and Characterization of CD8+ Tumor Infiltrating Lymphocytes from Renal Cell Carcinomas. Part V. Introduction. Immunomodulation and Antitumor Mechanisms. Interleukin-Induced Tumor Immunogenicity. Biological Significance of Autologous Tumor Killing. Biological Response Modifiers and Chemotherapeutic Agents that After Interleukin 2 Activities. Part VI. Introduction. Immunotherapy of Tumors. New Perspectives in Immunotherapy of Leukemia. The Role of Interferons in the Therapy of Melanoma. Therapy with Interleukin-2 and Tumor-Derived Activated Lymphocytes. Combination Cytokine Therapy in Cancer. Anti-Idiotype Antibodies: Novel Therapeutic Approach to Cancer Therapy. Immunity and Cancer Therapy: Present Status and Future Projections.
About the author
Goldfarb\, R. H.
